NCT06686576RecruitingPhase 3
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
A Phase Ib/III, Open-Label, Randomized Study of Neoadjuvant QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 363 (estimated)
- First submitted
- 11 Nov 2024
- Start date
- 12 Dec 2024
- Primary completion date
- Dec 2030
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Diseases
- Colorectal cancer
- NCT number
- NCT06686576
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 363
- From 12 Dec 2024 to the primary completion date, Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc
Other illness
- Has distant metastatic disease.
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has know history of, or any evidence of interstitial lung disease;
- Has an active infection requiring systemic therapy
Who the study is looking for
- Signed written informed consent;
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Untreated pathologically confirmed colon adenocarcinoma
- Radiographic assessment showed a resectable stage IIB-III based on AJCC Stage VIII (cT4 or cN+ only).
- Has a tumor demonstrating the presence of MSI-H/ dMMR
- Adequate organ function as described in the protocol
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Affiliated Cancer Hospital of Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.